| Biomarker ID | 813 |
| PMID | 22113713 |
| Year | 2012 |
| Biomarker | TGFβ1 (transforming growth factor beta 1) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Associated with Prostate cancer specific Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 10.4 (95% CI: 2.01–52.00) |
| Effect on Pathways | Pathways Include:-TGF-beta receptor activation of SMADs,NF-kappaB activation by non-typeable Hemophilus influenzae,Cell cycle: G1/S checkpoint, Syndecan 2 pathway,Signal transduction through IL-1R |
| Experiment | disease specific survival Vs no survival |
| Type of Biomarker | Prognostic |
| Cohort | 44 patients with prostate cancer who ubderwent radical prosteactomy were chosen for the study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Multivariate model considering Gleason Score, PSA, TGFb1 and IL-7. log-transformed expressions were used |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TGFB1 |